Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 9, 2020Frontiers in PharmacologyOpen Access

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYujeong KimEwha Womans UniversityHKHye-Young KwonMokwon UniversityBGBrian GodmanUniversity of Strathclyde

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kim et al. (2020) studied this question.

synapsesocial.com/papers/6a80206573f13514bdeeae6fhttps://doi.org/10.3389/fphar.2020.00970
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Saving money in the European healthcare systems with biosimilars2012 · 109 citations
  2. 2Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme2017 · 159 citations
  3. 3Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study2018 · 58 citations